Statement: Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial.
Primary_evidence: DISEASE CHARACTERISTICS:   Histologically confirmed stage IV breast cancer   Metastasis to the ipsilateral supraclavicular lymph nodes allowed   HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting   No effusions or ascites as only sites of disease   No primary or metastatic brain or central nervous system tumor   Hormone receptor status:   Not specified   PATIENT CHARACTERISTICS:   Age:   18 and over   Sex:   Female   Menopausal status:   Not specified Performance status:   Zubrod 0-2   Life expectancy:   Not specified   Hematopoietic:   Absolute neutrophil count at least 1,500/mm^3   Platelet count at least 100,000/mm^3   Hepatic:   Bilirubin normal   aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN)   Alkaline phosphatase no greater than 2.5 times ULN   Renal:   Not specified   Cardiovascular:   left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy)   No clinical evidence or history of cardiomyopathy   Other:   No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer   No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80   No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission   No known sensitivity to E. coli-derived proteins   Not pregnant or nursing   Negative pregnancy test   Fertile patients must use effective contraception   PRIOR CONCURRENT THERAPY:   Biologic therapy:   Not specified   Chemotherapy:   At least 6 months since prior chemotherapy   Prior anthracycline as adjuvant therapy allowed   No prior cumulative dose of doxorubicin more than 360 mg/m^2   No prior cumulative dose of epirubicin more than 720 mg/m^2   No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease   No prior docetaxel   No prior vinorelbine   Prior paclitaxel allowed   Endocrine therapy:   Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed   No concurrent hormonal therapy   Radiotherapy:   At least 3 weeks since prior radiotherapy   Surgery:   At least 2 weeks since prior surgery and recovered
Secondary_evidence: Inclusion Criteria:   Male and Female patients must be at least 18 years of age   Pathologically confirmed diagnosis of breast cancer   Metastatic or advanced stage breast cancer   Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy)   Patients with HER2+ disease must have received prior treatment with Trastuzumab   Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy   Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy)  3 weeks   Measurable disease by RECIST 1.1   Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090   Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1   Life expectancy of at least 3 months   Adequate hematologic function as defined by:   Absolute neutrophil count 1,500 cells/μL   Platelets 100,000/μL   Hemoglobin  9.0g/dL   Adequate hepatic function as defined by:   Serum bilirubin  1.5 X upper limit of normal (ULN);   Adequate renal function as defined by a serum creatinine  1.5 x ULN   AST, ALT, and alkaline phosphatase  3 × ULN except for:   Patients with hepatic metastases: ALT and AST  5 × ULN   Patients with hepatic and/or bone metastases: alkaline phosphatase  5 × ULN   Patients with Gilbert's disease: serum bilirubin < 5 mg/dL   Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures   Female subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment   Female subjects of childbearing age must have a negative serum pregnancy test at study entry. Exclusion Criteria:   Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease   Major surgery within 4 weeks prior to first dose of STA-9090   Poor peripheral venous access for study drug administration. Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material.   History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol [PEG] 300 and Polysorbate 80)   Baseline QTc > 470 msec   Ventricular ejection fraction (EF) <50% at baseline   Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)   Women who are pregnant or lactating   Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements   Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results in the judgment of the investigator   Seizure disorder or requirement for seizure medication   Prior treatment with an HSP90 inhibitor   persistent adverse events of prior therapies that are > 1 grade 1 in severity   history of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery   history of or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block   New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers or diuretics